HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Volker Steger Thorsten Walles Tobias Walker Godehard Friedel Permission Requests Citing Articles Citing Articles via HighWire Google Scholar Articles by Steger, V. Articles by Friedel, G. PubMed Articles by Steger, V. Articles by Friedel, G. Related Collections Lung - cancer

---

Original Articles: General Thoracic

Trimodal Therapy for Histologically Proven N2/3 Non–Small Cell Lung Cancer: Mid-Term Results and Indicators for Survival

^a Department of Thoracic Surgery, Schillerhöhe Hospital, Gerlingen, Germany
^b Department of Thoracic, Cardiac and Vascular Surgery, Tübingen University, Tübingen, Germany
^c Department of Mathematics, Stuttgart University, Stuttgart, Germany

Accepted for publication March 25, 2009.

^_* Address correspondence to Dr Steger, Department of Thoracic Surgery, Schillerhöhe Hospital, Solitudestr 18, Gerlingen, 70839, Germany (Email: vrsteger{at}gmx.de).

Background: Surgery alone for stage III non–small cell lung cancer provides a 5-year survival of 20% and competes with multimodal treatments. In 1999, a trimodal protocol was implemented at the Schillerhöhe Clinic. The aim of this study was to verify the feasibility and outcome of this trimodal protocol including survival, risk factors for survival, and comorbidity in a single institution.

Methods: Included were all patients with potentially resectable, previously untreated stage III non–small cell lung cancer operated on between February 1999 and May 2006 in the General Thoracic Surgery Unit of the Schillerhöhe Clinic following the same neoadjuvant protocol. Treatment-related morbidity, recurrence, survival after R0 resection, and risk factors for survival (pN0 after trimodal therapy, downstaging of International Union Against Cancer stage, T downstaging, N downstaging, regression rate, and histologic type of tumor) were analyzed.

Results: From 107 patients with stage III non–small cell lung cancer, 55 patients with mediastinoscopy-positive N2 or N3 were eligible for this study. Forty patients (72%) had the effect of International Union Against Cancer downstaging. Treatment-related comorbidity was 54% with hospital and 120-day mortality of 3.6% and 5.4%, respectively. Overall mean survival (Kaplan-Meier) was 43 months (95% confidence interval, 35 to 52) with an estimated 5-year survival rate of 49%. In multivariate testing, International Union Against Cancer downstaging after trimodal therapy achieved a level of significance (p = 0.031), and patients with UICC-downstaging after trimodal therapy had a mean survival of 53 months (95% confidence interval, 44 to 63) with an estimated 5-year survival rate of 60%.

Conclusions: Neoadjuvant trimodal treatment for histologically proven N2 or N3 stage III non–small cell lung cancer is promising and can, like no other approach at present time, considerably improve 5-year survival rates up to 63% in selected patients.

This article has been cited by other articles:

				T. Walles, M. Hampel, I. Dally, and G. Friedel eComment: Defective bronchial tissue homeostasis following neoadjuvant therapy for lung cancer Interactive CardioVascular and Thoracic Surgery, October 1, 2009; 9(4): 575 - 575. [Full Text] [PDF]